Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.49 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | G6PD | P11413 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD5 | P21918 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL873649 | 0.95 | SLC22A1 (0.51) | SLC22A1OPRM1EGFRALDH1A1LMNA | |
| SCHEMBL874700 | 0.95 | SLC22A1 (0.51) | SLC22A1OPRM1EGFRALDH1A1LMNA | |
| SCHEMBL30333892 | 0.83 | SLC22A1 (0.60) | SLC22A1OPRM1ALDH1A1LMNAKDM4E | |
| SCHEMBL14675624 | 0.83 | SLC22A1 (0.60) | SLC22A1OPRM1ALDH1A1LMNAKDM4E | |
| SCHEMBL1825788 | 0.78 | ALDH1A1 (0.47) | ALDH1A1LMNAGAAMAPTG6PD | |
| SCHEMBL2838600 | 0.76 | PTGS1 (0.56) | ALDH1A1LMNAKDM4ESMN1; SMN2GAA | |
| SCHEMBL1824464 | 0.75 | GPR17 (0.44) | ALDH1A1LMNAGAAMAPTG6PD | |
| SCHEMBL873048 | 0.75 | EGFR (0.60) | EGFRALDH1A1LMNAGAAMAPT | |
| SCHEMBL873049 | 0.75 | EGFR (0.60) | EGFRALDH1A1LMNAGAAMAPT | |
| SCHEMBL3573281 | 0.74 | ACHE (0.50) | ALDH1A1LMNAGAAMAPTG6PD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8552219-B2 | Process for preparing L-phenyl-3-dimethylaminopropane derivative | IND-SWIFT LABORATORIES LIMITED (IN) | 2013-10-08 | — | — | US | disclosed |
| EP-2619174-A1 | PROCESS FOR PREPARING L-PHENYL-3-DIMETHYLAMINOPROPANE DERIVATIVE | Ind-Swift Laboratories Limited (IN) | 2013-07-31 | — | — | EP | disclosed |
| US-20130190522-A1 | PROCESS FOR PREPARING L-PHENYL-3-DIMETHYLAMINOPROPANE DERIVATIVE | IND-SWIFT LABORATORIES LIMITED (IN) | 2013-07-25 | — | — | US | disclosed |
| WO-2012038974-A1 | PROCESS FOR PREPARING L-PHENYL-3-DIMETHYLAMINOPROPANE DERIVATIVE | IND-SWIFT LABORATORIES LIMITED (IN) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190522-A1 | PROCESS FOR PREPARING L-PHENYL-3-DIMETHYLAMINOPROPANE DERIVATIVE | CYP3A43, UGT1A1, UGT1A7 | OPRM1 1207/4885SLC22A1 1287/4885EGFR 1867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.